Bristol-Myers Squibb Co. BMY gained slightly Friday on news it brought a patent suit against Merck & Co., Inc. MRK related to a skin cancer drug.
Merck on Thursday won accelerated U.S. marketing approval for its Keytruda treatment for a common and deadly form of skin cancer. Bristol said the drug unlawfully exploits its May 20 immunotherapy patent.
Bristol-Myers, Roche Holding AG and Novartis AG are all at work on similar products. Bristol-Myers expects a decision from the Food and Drug Administration on its nivolumab skin cancer treatment in mid 2015.
The suit, filed Thursday in federal court in Wilmington, Delaware, is Bristol-Myers Squibb v. Merck & Co., 14-cv-01131, U.S. District Court, District of Delaware (Wilmington).
Bristol Myers closed at $51.12, up 1.1 percent.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.